Repligen to Report Fourth Quarter and Full Year 2020 Financial Results
February 11 2021 - 2:00PM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its fourth quarter and full year 2020 financial results
on Wednesday, February 24, 2021. The Company will issue a press
release before the market opens and will host a conference call at
8:30 a.m. EST to discuss business updates and financial results for
the three- and twelve- month reporting periods ended December 31,
2020.The conference call will be accessible by dialing toll-free
(844) 274-3999 for domestic callers and (412) 317-5607 for
international callers. No passcode is required for the live call.
In addition, a webcast will be accessible via the Investor
Relations section of the Company’s website. Both the conference
call and webcast will be archived for a period of time following
the live event. The replay dial-in numbers are (877) 344-7529 for
callers in the U.S., (855) 669-9658 for callers in Canada and (412)
317-0088 for international callers. Replay listeners must provide
the passcode 10151931.
About Repligen
CorporationRepligen Corporation is a global life sciences
company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. Our primary
customers are biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, Massachusetts, with
additional administrative and manufacturing operations worldwide.
The majority of our manufacturing sites are located in the U.S.
(California, Massachusetts, New Jersey and New York), and outside
of the U.S. we have sites in Estonia, Germany, Ireland, the
Netherlands and Sweden.This press release may contain
forward-looking statements within the meaning of the federal
securities laws. Investors are cautioned that statements in this
press release which are not strictly historical statements
including, without limitation, statements identified by words like
“believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including risks discussed from
time to time in our filings with the Securities and Exchange
Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Repligen Contact: Sondra S. NewmanGlobal Head of
Investor Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2023 to May 2024